Friedman / Anderson Managing Depression in Clinical Practice

1. Auflage 2010
ISBN: 978-1-84996-465-4
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 96 Seiten

An estimated 21 million people are diagnosed each year with a major depressive disorder in the USA, Western Europe and Japan. The economic cost of depression and its impact on sufferers and those around them is enormous. There are numerous therapy choices available, which can be daunting for the clinician trying to achieve the best treatment regimen. Managing Depression in Clinical Practice provides a concise overview of the clinical manifestation, diagnosis and management of this debilitating condition. The book gives practical coverage of depression in special populations, the management of treatment non-response and long-term treatment. Managing Depression in Clinical Practice is intended as an accessible text for family practitioners and psychiatrists in training and in practice. It will also be of interest to specialist nurses and allied health professionals working in the field.

Autoren/Hrsg.

Friedman, Edward S

Anderson, Ian M

Inhaltsverzeichnis

1;Managing Depression in Clinical Practice;3
1.1;Contents;5
1.2;Author biographies;7
1.3;Preface;9
1.4;Chapter 1 Classification, causes, and epidemiology;11
1.4.1;Different types of depression;11
1.4.1.1;Depressive disorders;11
1.4.2;Causes of depression;15
1.4.3;Epidemiology and natural history;18
1.4.4;References;20
1.5;Chapter 2 Depression in different types of patients;21
1.5.1;Depression in children;21
1.5.2;Depression in elderly people;22
1.5.3;Depression in women;23
1.5.4;Depression in patients with comorbid medical conditions;24
1.5.5;References;25
1.6;Chapter 3 Diagnosis;26
1.6.1;Signs and symptoms of depression;26
1.6.2;Differential diagnosis;28
1.6.3;The patient examination and interview;29
1.6.4;Laboratory tests for co-occurring illnesses;33
1.6.5;References;34
1.7;Chapter 4 Principles of therapy;35
1.7.1;Goals of treatment;35
1.7.1.1;Rating scales for assessment of outcomes;36
1.7.1.2;Acute treatment outcomes;36
1.7.1.3;Medium- and long-term treatment outcomes;38
1.7.2;Treatment options;39
1.7.2.1;Nonspecific effects and placebo;39
1.7.2.2;Specific treatment options;39
1.7.3;Choice of treatment;40
1.7.3.1;Thresholds for benefit from specific treatments;40
1.7.3.2;Choice between specific treatments;42
1.7.4;Practicalities of treatment;43
1.7.4.1;Evaluation of risk, education, and agreeing treatment;43
1.7.4.2;Special populations;45
1.7.4.3;Children and adolescents;45
1.7.4.4;Elderly people;45
1.7.4.5;Pregnancy and breastfeeding;46
1.7.4.6;Initiating treatment;46
1.7.4.7;Monitoring and adjusting treatment;47
1.7.4.8;Service structure in delivery of treatment;48
1.7.5;Factors affecting response to treatment;49
1.7.6;References;50
1.8;Chapter 5 Medications;52
1.8.1;Selective serotonin reuptake inhibitors;53
1.8.2;Serotonin and norepinephrine reuptake inhibitors;55
1.8.2.1;Venlafaxine;55
1.8.2.2;Duloxetine;56
1.8.2.3;Milnacipran;56
1.8.3;Monoamine receptor antagonist drugs;56
1.8.3.1;Trazodone and nefazodone;56
1.8.3.2;Mirtazapine;57
1.8.4;Norepinephrine reuptake inhibitors;58
1.8.4.1;Reboxetine;58
1.8.5;Dopamine reuptake inhibitors;58
1.8.5.1;Bupropion (amfebutamone);58
1.8.6;Tricyclic antidepressants;59
1.8.7;Monoamine oxidase inhibitors;61
1.8.8;Other drugs;62
1.8.8.1;New compounds;62
1.8.8.2;Augmentation strategies;63
1.8.9;Specific adverse effects of antidepressants;63
1.8.9.1;Serotonin syndrome;63
1.8.9.2;Antidepressant discontinuation syndrome;63
1.8.9.3;Suicidality;64
1.8.10;References;65
1.9;Chapter 6 Other treatments;66
1.9.1;Psychotherapy for depression;66
1.9.2;Combination psychotherapy and psychopharmacotherapy for depression;68
1.9.3;Physical treatments;71
1.9.3.1;Electroconvulsive therapy;71
1.9.3.2;Phototherapy;73
1.9.3.3;Other physical treatments;73
1.9.3.4;Vagus nerve stimulation;74
1.9.3.5;Transcranial magnetic stimulation;74
1.9.3.6;Deep brain stimulation;75
1.9.4;Lifestyle and complementary therapies;75
1.9.4.1;Exercise;76
1.9.4.2;St John’s wort;77
1.9.4.3;Omega-3-fatty acids;77
1.9.4.4;Acupuncture;78
1.9.5;References;80
1.10;Chapter 7 Management of treatment nonresponse;83
1.10.1;Assessment and principles of management;83
1.10.1.1;Assessment;83
1.10.1.2;Principles of management;84
1.10.2;Definitions: treatment nonresponse and treatment-resistant depression;85
1.10.3;Medication strategies;86
1.10.3.1;Dose increase;86
1.10.3.2;Switching treatment;86
1.10.3.3;Combining treatments;87
1.10.4;Psychological treatment strategies;88
1.10.5;Physical treatment strategies;89
1.10.6;References;90
1.11;Chapter 8 Continuation and maintenance treatment;91
1.11.1;Goals of continuation/maintenance treatment;91
1.11.2;Phases of treatment;91
1.11.3;Medication;92
1.11.4;Psychological treatments;93
1.11.5;Physical treatments;94
1.11.6;Risk factors for relapse and recurrence;94
1.11.7;Longer-term treatment in practice;94
1.11.8;References;96
1.12;Index;97